```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:59:21 ON 31 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 31 Jan 2005  VOL 142 ISS 6
FILE LAST UPDATED: 30 Jan 2005  (20050130/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d que l18
L1       130621 SEA FILE=REGISTRY HAV/SQSP
L2      4596912 SEA FILE=REGISTRY SQL<=25
L3         1017 SEA FILE=REGISTRY L1 AND L2
L4          217 SEA FILE=REGISTRY L3 AND S>=2 AND S<=22
L5          110 SEA FILE=REGISTRY [C'MPA''PEN']HAV[C'MPA''PEN']/SQSP
L7           57 SEA FILE=REGISTRY L2 AND L5
L8          218 SEA FILE=REGISTRY L4 OR L7
L10          82 SEA FILE=HCAPLUS L8
L11          25 SEA FILE=HCAPLUS L10 AND CYCLIC
L12          19 SEA FILE=HCAPLUS L11 AND (BLASCHUK?/AU OR GOUR?/AU OR FAROOKHI?
                /AU OR ALI?/AU)
L13           1 SEA FILE=HCAPLUS L10 AND (VASCULAR(5A)SMOOTH(5A)MUSC?)
L14          25 SEA FILE=HCAPLUS L11 OR L12 OR L13
L15             TRANSFER  L14 1-25 RN :    1531 TERMS
L16        1531 SEA FILE=REGISTRY L15
L17         169 SEA FILE=REGISTRY L8 AND L16
L18           1 SEA FILE=HCAPLUS L17 AND L13


=> d ibib abs hitrn l18 1

L18  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:451625  HCAPLUS
DOCUMENT NUMBER:          141:17645
TITLE:                    Cadherin cell adhesion recognition sequence
                          (HAV)-containing cyclic peptides and methods for
                          modulating cell adhesion and therapeutic applications
INVENTOR(S):              Blaschuk, Orest W.; Gour, Barbara J.; Farookhi, Riaz;
                          Ali, Anmar
PATENT ASSIGNEE(S):       Can.
SOURCE:                   U.S. Pat. Appl. Publ., 147 pp., Cont.-in-part of U.S.
                          Ser. No. 464,071.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
```

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004106545	A1	20040603	US 2003-632678	20030801
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6346512	B1	20020212	US 1999-248074	19990210
US 6562786	B1	20030513	US 1999-248015	19990210
US 6417325	B1	20020709	US 1999-357717	19990720
US 6465427	B1	20021015	US 1999-458870	19991210
US 6610821	B1	20030826	US 2000-544782	20000407
US 2003224978	A1	20031204	US 2003-359546	20030204

PRIORITY APPLN. INFO.:

US 1996-21612P	P	19960712
US 1997-893534	A2	19970711
US 1997-996679	A2	19971223
US 1999-248015	A1	19990210
US 1999-248074	A2	19990210
US 1999-357717	A2	19990720
US 1999-458870	A2	19991210
US 2000-544782	A1	20000407
US 2003-359546	A2	20030204
US 2003-464071	A2	20030618

OTHER SOURCE(S): MARPAT 141:17645

AB Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compns. comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided. Specifically, the representative cyclic peptides are shown to inhibit neurite outgrowth, disrupt various tumor epithelial cell adhesions, block angiogenesis, enhance skin permeability, and inhibit migration and regulate apoptosis of **vascular smooth muscle** cells. The effect of sequences that flank the HAV sequence, sequences external to the cyclic peptide ring and terminal modifications on specificity for N-cadherin-mediated responses are studied. In addition, the toxicity and stability of these cyclic peptides are also evaluated.

IT **229971-81-7 229971-83-9 229971-84-0**
229971-85-1 229971-86-2 229971-87-3
263917-87-9 263917-88-0 263917-89-1
263917-90-4 263917-91-5 263917-92-6
263917-93-7 331229-54-0 365544-51-0
365544-52-1 365544-53-2 365544-54-3
365544-56-5 365544-57-6 365544-58-7
381224-69-7 381224-80-2 469860-50-2
469860-51-3 469860-52-4 469860-53-5
469860-57-9 469860-58-0 469860-62-6
698347-70-5 698347-71-6 698347-72-7
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin cell adhesion recognition sequence HAV-containing cyclic peptides; cadherin cell adhesion recognition sequence (HAV)-containing cyclic peptides and methods for modulating cell adhesion and therapeutic applications)

IT **471258-25-0 471258-26-1**
RL: PRP (Properties)
(unclaimed sequence; cadherin cell adhesion recognition sequence (HAV)-containing cyclic peptides and methods for modulating cell adhesion

and therapeutic applications)

```
=> d que l19
L1       130621 SEA FILE=REGISTRY HAV/SQSP
L2      4596912 SEA FILE=REGISTRY SQL<=25
L3         1017 SEA FILE=REGISTRY L1 AND L2
L4          217 SEA FILE=REGISTRY L3 AND S>=2 AND S<=22
L5          110 SEA FILE=REGISTRY [C'MPA''PEN']HAV[C'MPA''PEN']/SQSP
L7           57 SEA FILE=REGISTRY L2 AND L5
L8          218 SEA FILE=REGISTRY L4 OR L7
L10          82 SEA FILE=HCAPLUS L8
L11          25 SEA FILE=HCAPLUS L10 AND CYCLIC
L12          19 SEA FILE=HCAPLUS L11 AND (BLASCHUK?/AU OR GOUR?/AU OR FAROOKHI?
                /AU OR ALI?/AU)
L13           1 SEA FILE=HCAPLUS L10 AND (VASCULAR(5A)SMOOTH(5A)MUSC?)
L14          25 SEA FILE=HCAPLUS L11 OR L12 OR L13
L15             TRANSFER  L14 1-25 RN :    1531 TERMS
L16        1531 SEA FILE=REGISTRY L15
L17         169 SEA FILE=REGISTRY L8 AND L16
L19          24 SEA FILE=HCAPLUS L17 AND (L14 NOT L13)


=> d ibib abs hitrn l19 1-24

L19  ANSWER 1 OF 24  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:996202  HCAPLUS
DOCUMENT NUMBER:          142:2500
TITLE:                    Selective R-cadherin peptide antagonists and use for
                          treating vascular diseases
INVENTOR(S):              Friedlander, Martin; Dorrell, Michael I.
PATENT ASSIGNEE(S):       The Scripps Research Institute, USA
SOURCE:                   PCT Int. Appl., 55 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004099232         A2    20041118    WO 2004-US13212          20040430
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     US 2005004013         A1    20050106    US 2004-836289           20040430
PRIORITY APPLN. INFO.:                       US 2003-467188P      P   20030501
AB   An isolated peptide useful as a selective antagonist of mammalian
     R-cadherin comprises 3 to 30 amino acid residues, three contiguous
     residues of the peptide having the amino acid sequence Ile-Xaa-Ser;
     wherein Xaa is an amino acid residue selected from the group consisting of
```

Asp, Asn, Glu, and Gln. Preferably Xaa is Asp or Asn. In one preferred embodiment the peptide is a **cyclic** peptide having 3 to 10 amino acid residues arranged in a ring. The selective R-cadherin antagonist peptides of the invention are useful for inhibiting the targeting of stem cells, such as endothelial precursor cells, to developing vasculature, for inhibiting R-cadherin mediated cellular adhesion, and for inhibiting retinal angiogenesis.

IT **202527-94-4**
RL: PRP (Properties)
(unclaimed sequence; selective R-cadherin peptide antagonists and use for treating vascular diseases)

L19 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:681661 HCAPLUS
DOCUMENT NUMBER: 141:202271
TITLE: Cloning and physical characterization of human phosphodiesterases PDE7A, PDE9A, and PDE10A, and their use for drug screening
INVENTOR(S): Mendlein, John D.; Pan, James Guohua; Dharamsi, Akil; Domagala, Megan; Mamelak, Daniel; McDonald, Merry-Lynn; Wang, Peixiang
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069989	A2	20040819	WO 2004-CA167	20040209

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-446019P	P	20030207
US 2003-452282P	P	20030305
US 2003-492799P	P	20030806

AB The present invention relates to novel compns. of phosphodiesterase polypeptides. The cDNA sequences and the encoding amino acid sequences of PDE7A from human thyroid gland, PDE9A of human brain, and PDE10A of human brain, and truncation fragments thereof are provided. The invention also provides biochem. and biophys. characteristics of the polypeptides of the invention, in particular characterization by mass spectrometry, x-ray crystallog. and NMR spectrometry. The polypeptides of the invention are used for drug screening.

IT **743429-09-6 743429-38-1**
RL: PRP (Properties)
(unclaimed sequence; cloning and phys. characterization of human phosphodiesterases PDE7A, PDE9A, and PDE10A, and their use for drug

screening)

L19 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:485562 HCAPLUS
DOCUMENT NUMBER: 141:22968
TITLE: Computer method and apparatus for classifying objects such as protein sequences and its application with **cyclic** peptide osteogenic modulators of bone morphogenetic protein-7
INVENTOR(S): Keck, Peter
PATENT ASSIGNEE(S): Thrasos, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 58 pp., Cont. of Appl. No. PCT/US01/44000.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004039543	A1	20040226	US 2003-430685		20030506
PRIORITY APPLN. INFO.:			US 2000-246196P	P	20001106
			WO 2001-US44000	A1	20011106

AB A computer classification method and apparatus employs statistical anal. of known objects in the class of interest. For each known object in the class, a resp. vector of q bits is formed. Each bit indicates presence or absence of an activity or phys. property in the object. The probability that a bit is equal to 1 in the class is then applied to vector representations of test objects and dets. probability of the test object belonging to the class. Protein sequences are objects, a set of sequences similar enough to be aligned as a superfamily constitutes a collection, and the aligned sequence positions are components. In this case all components have the same standard set of elements which is the 20 naturally occurring amino acids and so have the same vector width. The 12 features making up the feature set are: hydrophobicity, helix propensity, sheet propensity, hydrogen donor propensity, hydrogen acceptor propensity, the state of being charged, aromaticity, side chain linearity (unbranched), medium sidechain volume, large sidechain volume, Phi-Psi flexibility, and crosslinkability (disulfide bond formation). An embodiment of the present invention is classification of **cyclic** polypeptides that can modulate the activity of bone morphogenetic proteins (BMP), particularly BMP-7.
IT **697749-13-6**
RL: PRP (Properties)
(unclaimed sequence; computer method and apparatus for classifying objects such as protein sequences and its application with **cyclic** peptide osteogenic modulators of bone morphogenetic protein-7)

L19 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:364264 HCAPLUS
DOCUMENT NUMBER: 141:184992
TITLE: A dimeric version of the short N-cadherin binding motif HAVDI promotes neuronal cell survival by activating an N-cadherin/fibroblast growth factor receptor signalling cascade
AUTHOR(S): Skaper, Stephen D.; Facci, Laura; Williams, Gareth; Williams, Emma-Jane; Walsh, Frank S.; Doherty, Patrick
CORPORATE SOURCE: Neurology & GI Centre of Excellence for Drug

Discovery, GlaxoSmithKline Research & Development Limited, Essex, CM19 5AW, UK
SOURCE: Molecular and Cellular Neuroscience (2004), 26(1), 17-23
CODEN: MOCNED; ISSN: 1044-7431
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The HAVDI and INPISGQ sequences have been identified as functional binding motifs in extracellular domain 1 (ECD1) of N-cadherin. **Cyclic** peptides containing a tandem repeat of the individual motifs function as N-cadherin agonists and stimulate neurite outgrowth. The authors now show that the **cyclic** peptide N-Ac-CHAVDINGHAVDIC-NH2 (SW4) containing the HAVDI sequence in tandem is efficacious also in promoting the in vitro survival of several populations of central nervous system neurons in paradigms where fibroblast growth factor-2 (FGF-2) is active. SW4 supported the survival of rat postnatal cerebellar granule neurons plated in serum-free medium and limited the death of differentiated granule neurons induced to die by switch to low K+ medium. In addition, SW4 rescued embryonic hippocampal and cortical neurons from injury caused by glutamic acid excitotoxicity. The neuroprotective effects of SW4 displayed a concentration dependence similar to those inducing neuritogenesis, were inhibited by a monomeric version of the same motif and by a specific FGF receptor antagonist (PD173074), and were not mimicked by the linear peptide. Inhibitors of the phosphatidylinositol 3-kinase (PI 3-kinase), MAP kinase, and p38 kinase signaling pathways did not interfere with SW4 function. These data suggest that SW4 functions by binding to and clustering N-cadherin in neurons and thereby activating and N-cadherin/FGF receptor signaling cascade, and propose that such agonists may represent a starting point for the development of therapeutic agents promoting neuronal cell survival and regeneration.

IT **462127-36-2**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dimeric version of short N-cadherin binding motif HAVDI promotes neuronal cell survival by activating an N-cadherin/fibroblast growth factor receptor signalling cascade)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:70027 HCAPLUS
DOCUMENT NUMBER: 140:139536
TITLE: Compounds and methods for stimulating gene expression and cellular differentiation
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 57,363.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6683048	B1	20040127	US 1999-265107	19990309
US 6551994	B1	20030422	US 1998-57363	19980408

WO 2000053632 A1 20000914 WO 2000-CA222 20000307
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2003236186 A1 20031225 US 2003-369226 20030213
PRIORITY APPLN. INFO.: US 1997-43361P P 19970410
US 1998-57363 A2 19980408
US 1999-265107 A 19990309

AB Modulating agents for inhibiting an interaction between α-catenin and β-catenin are provided by increasing the level of free β-catenin in a cell cytoplasm. The present invention relates generally to compds. and methods for use in stimulating β-catenin mediated gene expression and cellular differentiation. The modulating agents comprise one or more of: (a) a β-catenin HAV motif; (b) a peptide analog or mimetic of a β-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a β-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **214684-19-2 214684-20-5 214684-26-1**
214684-27-2 214684-29-4 214684-37-4
214684-38-5 214684-40-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stimulation of β-catenin mediated cellular differentiation by inhibiting interaction between α-catenin and β-catenin using a peptide analog having a HAV motif with internalization moiety)

IT **202527-94-4 214684-28-3 214684-33-0**
214684-35-2 214684-36-3
RL: PRP (Properties)
(unclaimed sequence; compds. and methods for stimulating gene expression and cellular differentiation)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:20322 HCAPLUS
DOCUMENT NUMBER: 140:87658
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): **Gour, Barbara J.; Blaschuk, Orest W.**; **Ali, Anmar**; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2004006011	A1	20040108	US 2003-425557	20030428
US 6031072	A	20000229	US 1997-893534	19970711
US 6326352	B1	20011204	US 2000-507102	20000217
US 2002168761	A1	20021114	US 2001-769145	20010124
US 2002151475	A1	20021017	US 2001-6982	20011204
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A1 19970711
			US 2000-491078	B2 20000124
			US 2000-507102	A1 20000217
			US 2001-769145	B2 20010124
			US 2001-6982	A2 20011204

OTHER SOURCE(S): MARPAT 140:87658

AB Peptidomimetics of **cyclic** peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a **cyclic** peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **229971-59-9**, L-Cysteinamide, L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→5)-disulfide **229971-81-7**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→5)-disulfide **229971-83-9**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, **cyclic** (1→8)-disulfide **229971-84-0**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-, **cyclic** (1→6)-disulfide **229971-85-1**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→7)-disulfide **229971-86-2**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, **cyclic** (1→8)-disulfide **229971-87-3**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→6)-disulfide **229971-89-5**, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→7)-disulfide **229971-90-8**, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, **cyclic** (1→8)-disulfide **263917-87-9**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→8)-disulfide **263917-88-0**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→6)-disulfide **263917-89-1**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→6)-disulfide **263917-90-4**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→8)-disulfide **263917-92-6**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-, **cyclic** (1→7)-disulfide **263917-93-7**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, **cyclic** (1→7)-disulfide **331229-54-0**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→9)-disulfide **365544-54-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
250271-33-1 250271-34-2 250271-35-3
250271-36-4 250271-37-5 250271-39-7
250271-41-1 351974-94-2 351974-95-3
351974-97-5 351974-98-6 351974-99-7
351975-00-3 351975-01-4 351975-02-5
351975-03-6 351975-04-7 351975-05-8
352000-59-0 352000-60-3 352335-43-4
352335-47-8
RL: PRP (Properties)
(unclaimed protein sequence; peptidomimetic modulators of cell adhesion)

L19 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:667398 HCAPLUS
DOCUMENT NUMBER: 139:207819
TITLE: Cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.; Farookhi, Riaz; Ali, Anmar**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 71 pp., Cont.-in-part of U.S. 6,465,427.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6610821	B1	20030826	US 2000-544782	20000407
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6346512	B1	20020212	US 1999-248074	19990210
US 6417325	B1	20020709	US 1999-357717	19990720
US 6465427	B1	20021015	US 1999-458870	19991210
CA 2405476	AA	20011018	CA 2001-2405476	20010409
WO 2001077146	A2	20011018	WO 2001-US11669	20010409
WO 2001077146	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1311545	A2	20030521	EP 2001-926823	20010409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531120	T2	20031021	JP 2001-575616	20010409
US 2004106545	A1	20040603	US 2003-632678	20030801
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A2 19970711

US 1997-996679	A2	19971223
US 1999-248074	A2	19990210
US 1999-357717	A2	19990720
US 1999-458870	A2	19991210
US 1999-248015	A1	19990210
US 2000-544782	A	20000407
WO 2001-US11669	W	20010409
US 2003-359546	A2	20030204
US 2003-464071	A2	20030618

OTHER SOURCE(S): MARPAT 139:207819

AB **Cyclic** peptides comprising a cadherin cell adhesion recognition sequence HAV, and compns. comprising such **cyclic** peptides, are provided. Methods for using such peptides for modulating cadherin-mediated endothelial cell adhesion in a variety of contexts are also provided.

IT **229971-59-9**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion in relation to angiogenesis inhibition and antitumor activity)

IT **229971-81-7P 365544-54-3P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion in relation to angiogenesis inhibition and antitumor activity)

IT **229971-83-9 229971-84-0 229971-85-1**
229971-86-2 229971-87-3 229971-90-8
263917-88-0
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion in relation to angiogenesis inhibition and antitumor activity)

IT **214684-49-8 229971-60-2 229971-61-3**
229971-62-4 229971-63-5 229971-64-6
229971-65-7 229971-67-9 365544-42-9
365544-43-0 365544-44-1 365544-45-2
365544-46-3 365544-47-4 365544-48-5
365544-49-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion in relation to angiogenesis inhibition and antitumor activity)

IT **331474-61-4 331474-62-5 469860-57-9**
469860-58-0
RL: PRP (Properties)
(unclaimed protein sequence; cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion)

IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
250271-33-1 250271-34-2 250271-35-3
250271-36-4 250271-37-5 250271-39-7
250271-41-1 331474-58-9 351974-94-2

351974-95-3 351974-97-5 351974-98-6
351974-99-7 351975-00-3 351975-01-4
351975-02-5 351975-03-6 351975-04-7
351975-05-8 352000-59-0 352000-60-3
352335-43-4 352335-47-8 471258-23-8
471258-24-9 471258-25-0
RL: PRP (Properties)
(unclaimed sequence; cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion)

REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:368600 HCAPLUS
DOCUMENT NUMBER: 138:362656
TITLE: Compounds and methods for modulating apoptosis
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 84 pp., Cont.-in-part of U.S. 6,167,071.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6562786	B1	20030513	US 1999-248015	19990210
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 2003224978	A1	20031204	US 2003-359546	20030204
US 2004106545	A1	20040603	US 2003-632678	20030801
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A2 19970711
			US 1997-996679	A2 19971223
			US 1999-248015	A1 19990210
			US 1999-248074	A2 19990210
			US 1999-357717	A2 19990720
			US 1999-458870	A2 19991210
			US 2000-544782	A1 20000407
			US 2003-359546	A2 20030204
			US 2003-464071	A2 20030618

OTHER SOURCE(S): MARPAT 138:362656
AB **Cyclic** peptides and compns. comprising such **cyclic** peptides are provided. The **cyclic** peptides comprise a classical cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for inducing apoptosis in cadherin-expressing cells, such as cancer cells, are also provided.
IT **202528-21-0 202528-23-2 521918-73-0**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for modulating apoptosis using **cyclic** peptides with cadherin cell adhesion recognition sequence HAV in relation to disruption of cell adhesion)
IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
202528-19-6 202528-20-9 202528-22-1
250271-33-1 250271-34-2 250271-35-3

250271-36-4 250271-37-5 250271-39-7
250271-41-1 351974-94-2 351974-95-3
351974-97-5 382656-75-9 382656-76-0
521918-75-2 521918-76-3 521918-77-4
521918-78-5 521918-79-6 521918-80-9
521918-81-0 521918-82-1 521918-83-2
521918-84-3 521918-85-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for modulating apoptosis using **cyclic** peptides with cadherin cell adhesion recognition sequence HAV in relation to disruption of cell adhesion)
REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:869496 HCAPLUS
DOCUMENT NUMBER: 137:363033
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): **Gour, Barbara J.; Blaschuk, Orest W.** ; **Ali, Anmar**; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002168761	A1	20021114	US 2001-769145	20010124
US 2004058864	A1	20040325	US 2003-412701	20030410
US 2004006011	A1	20040108	US 2003-425557	20030428
PRIORITY APPLN. INFO.:			US 2000-491078	A2 20000124
			US 1996-21612P	P 19960712
			US 1997-893534	A1 19970711
			US 2000-507102	A1 20000217
			US 2001-769145	B1 20010124
			US 2001-6982	A2 20011204

OTHER SOURCE(S): MARPAT 137:363033
AB Peptidomimetics of **cyclic** peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a **cyclic** peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT **229971-59-9**, L-Cysteinamide, L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→5)-disulfide **229971-81-7**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→5)-disulfide **229971-83-9**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, **cyclic** (1→8)-disulfide **229971-84-0**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-, **cyclic** (1→6)-disulfide **229971-85-1**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-

histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→7)-disulfide **229971-86-2**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, **cyclic** (1→8)-disulfide **229971-87-3**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→6)-disulfide **229971-89-5**, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→7)-disulfide **229971-90-8**, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, **cyclic** (1→8)-disulfide **263917-87-9**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→8)-disulfide **263917-88-0**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-, **cyclic** (1→6)-disulfide **263917-89-1**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→6)-disulfide **263917-90-4**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→8)-disulfide **263917-92-6**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-, **cyclic** (1→7)-disulfide **263917-93-7**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, **cyclic** (1→7)-disulfide **331229-54-0**, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, **cyclic** (1→9)-disulfide

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT **202527-94-4 202527-98-8 202528-00-5 202528-03-8 202528-07-2 202528-10-7 250271-33-1 250271-34-2 250271-35-3 250271-36-4 250271-37-5 250271-39-7 250271-41-1 351974-94-2 351974-95-3 351974-97-5 351974-98-6 351974-99-7 351975-00-3 351975-01-4 351975-02-5 351975-03-6 351975-04-7 351975-05-8 352000-59-0 352000-60-3 352335-43-4 352335-47-8**

RL: PRP (Properties)

(unclaimed sequence; peptidomimetic modulators of cell adhesion)

L19 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:790218 HCAPLUS
DOCUMENT NUMBER: 137:304806
TITLE: HAV-containing **cyclic** peptides and methods using them for modulating cell adhesion
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.; Farookhi, Riaz; Ali, Anmar**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 126 pp., Cont.-in-part of U.S. Ser. No. 357,717.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6465427	B1	20021015	US 1999-458870	19991210
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6346512	B1	20020212	US 1999-248074	19990210
US 6417325	B1	20020709	US 1999-357717	19990720
US 6610821	B1	20030826	US 2000-544782	20000407
US 2003065136	A1	20030403	US 2002-105008	20020322
US 2004106545	A1	20040603	US 2003-632678	20030801
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A2 19970711
			US 1997-996679	A2 19971223
			US 1999-248074	A2 19990210
			US 1999-357717	A2 19990720
			US 1999-248015	A1 19990210
			US 1999-458870	A2 19991210
			US 2000-544782	A1 20000407
			US 2003-359546	A2 20030204
			US 2003-464071	A2 20030618

OTHER SOURCE(S): MARPAT 137:304806

AB **Cyclic** peptides comprising a cadherin cell adhesion recognition sequence HAV, and compns. comprising such **cyclic** peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **214684-49-8 229971-81-7 229971-83-9**
229971-84-0 229971-85-1 229971-86-2
229971-87-3 229971-89-5 229971-90-8
263917-87-9 263917-88-0 263917-89-1
263917-90-4 263917-91-5 263917-92-6
263917-93-7 331229-54-0 365544-42-9
365544-43-0 365544-44-1 365544-45-2
365544-46-3 365544-47-4 365544-48-5
365544-49-6 365544-51-0 365544-52-1
365544-53-2 365544-53-2 365544-54-3
365544-55-4 365544-56-5 365544-57-6
365544-58-7 365544-59-8 365544-72-5
365544-73-6 365544-74-7 365544-75-8
365544-76-9 365544-77-0 365544-78-1
365544-79-2 381224-69-7 381224-80-2
469860-50-2 469860-51-3 469860-52-4
469860-53-5 469860-56-8 469860-57-9
469860-58-0 469860-61-5 469860-62-6
469860-63-7 471331-41-6
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HAV-containing **cyclic** peptides for modulating cell adhesion)

IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
250271-33-1 250271-34-2 250271-35-3
250271-36-4 250271-37-5 250271-39-7
250271-41-1 351974-94-2 351974-95-3
351974-97-5 351974-98-6 351974-99-7
351975-00-3 351975-01-4 351975-02-5
351975-03-6 351975-04-7 351975-05-8
352000-59-0 352000-60-3 352335-43-4
352335-47-8 471258-23-8 471258-24-9

471258-25-0 471258-26-1
RL: PRP (Properties)
(unclaimed sequence; hAV-containing **cyclic** peptides and methods using them for modulating cell adhesion)
REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:516694 HCAPLUS
DOCUMENT NUMBER: 137:88441
TITLE: Compounds and methods for cancer therapy using cadherin cell adhesion recognition **cyclic** peptides
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J. ; Farookhi, Riaz**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 61 pp., Cont.-in-part of U.S. Ser. No. 248,074.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6417325	B1	20020709	US 1999-357717	19990720
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6346512	B1	20020212	US 1999-248074	19990210
US 6465427	B1	20021015	US 1999-458870	19991210
US 6610821	B1	20030826	US 2000-544782	20000407
US 2003087811	A1	20030508	US 2002-58821	20020129
US 6780845	B2	20040824		
US 2003065136	A1	20030403	US 2002-105008	20020322
US 2004106545	A1	20040603	US 2003-632678	20030801
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A2 19970711
			US 1997-996679	A2 19971223
			US 1999-248074	A2 19990210
			US 1999-248015	A1 19990210
			US 1999-357717	A2 19990720
			US 1999-458870	A2 19991210
			US 2000-544782	A1 20000407
			US 2003-359546	A2 20030204
			US 2003-464071	A2 20030618

AB Agents that inhibit the development of cancer and tumor growth are provided. Such agents comprise a classical cadherin cell adhesion recognition (CAR) sequence HAV within a **cyclic** peptide ring, and may be used to prevent or treat cancer. The **cyclic** peptide N-Ac-CHAVC-NH2 disrupted melanoma cell adhesion and inhibited angiogenesis.
IT **214684-49-8 229971-60-2 229971-61-3 229971-62-4 229971-63-5 229971-64-6 229971-65-7 229971-67-9 229971-68-0 229971-69-1 229971-70-4 229971-71-5 229971-72-6 381224-65-3 381224-66-4 381224-67-5**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cell adhesion modulating **cyclic** peptide; compds. and methods for cancer therapy using cadherin cell adhesion recognition **cyclic** peptides)

IT **229971-59-9**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for cancer therapy using cadherin cell adhesion recognition **cyclic** peptides)

IT **229971-81-7 229971-83-9 229971-84-0 229971-85-1 229971-86-2**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for cancer therapy using cadherin cell adhesion recognition **cyclic** peptides)

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:150931 HCAPLUS
DOCUMENT NUMBER: 137:260472
TITLE: Dimeric versions of two short N-cadherin binding motifs (HAVDI and INPISG) function as N-cadherin agonists
AUTHOR(S): Williams, Gareth; Williams, Emma-Jane; Doherty, Patrick
CORPORATE SOURCE: Molecular Neurobiology Group, Medical Research Council Centre for Developmental Neurobiology, King's College London, London, SE1 1UL, UK
SOURCE: Journal of Biological Chemistry (2002), 277(6), 4361-4367
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N-cadherin is a member of the classical cadherin family of homophilic binding mols. Peptide competition studies have identified the HAVDI and INPISGQ sequences as functional binding motifs in extracellular domain 1 (ECD1) of N-cadherin. Whereas monomeric versions of these motifs function as specific N-cadherin antagonists, we now show that **cyclic** peptides containing a tandem repeat of the individual motifs function as N-cadherin agonists. In this context, when presented to neurons as soluble mols., the dimeric versions of the motifs stimulate neurite outgrowth in a similar manner to native N-cadherin. The response to the dimeric agonist peptides was inhibited by monomeric versions of the same motif and also by recombinant N-cadherin ECD1 protein. The responses were also inhibited by antibodies to a fibroblast growth factor receptor (FGFR) binding motif in ECD4 of N-cadherin and by a specific FGFR antagonist (PD17304). These data suggest that the peptides function by binding to and clustering N-cadherin in neurons and thereby activating an N-cadherin/FGFR signaling cascade. The novel agonists will be invaluable for dissecting out those cadherin functions that rely on signaling as opposed to adhesion and clearly have the potential to be developed as therapeutic agents for the promotion of cell survival and axonal regeneration.

IT **462127-36-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(dimeric versions of two short N-cadherin binding motifs (HAVDI and INPISG) function as N-cadherin agonists)

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:114061 HCAPLUS
DOCUMENT NUMBER: 136:161398
TITLE: Compounds and methods for modulating cell adhesion
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 94 pp., Cont.-in-part of U.S. Ser. No. 996,679.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6346512	B1	20020212	US 1999-248074	19990210
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6417325	B1	20020709	US 1999-357717	19990720
US 6465427	B1	20021015	US 1999-458870	19991210
US 6610821	B1	20030826	US 2000-544782	20000407
US 2003087811	A1	20030508	US 2002-58821	20020129
US 6780845	B2	20040824		
US 2003065136	A1	20030403	US 2002-105008	20020322
US 2004106545	A1	20040603	US 2003-632678	20030801

PRIORITY APPLN. INFO.:

US 1996-21612P	P	19960712
US 1997-893534	A2	19970711
US 1997-996679	A2	19971223
US 1999-248015	A1	19990210
US 1999-248074	A2	19990210
US 1999-357717	A2	19990720
US 1999-458870	A2	19991210
US 2000-544782	A1	20000407
US 2003-359546	A2	20030204
US 2003-464071	A2	20030618

AB **Cyclic** peptides and compns. comprising such **cyclic** peptides are provided. The **cyclic** peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided. Antibodies or Fab fragments directed against a cadherin cell adhesion recognition sequence and/or an occludin cell adhesion recognition sequence may also be employed; either incorporated into a modulating agent or within a sep. modulator that is administered concurrently. Such uses include enhancing drug delivery to the central nervous system and linking the modulating agent to a drug.

IT **214684-49-8 229971-59-9 229971-60-2**
229971-61-3 229971-62-4 229971-63-5
229971-64-6 229971-65-7 229971-67-9
229971-68-0 229971-69-1 229971-70-4
229971-71-5 229971-72-6 229971-81-7
229971-83-9 229971-84-0 229971-85-1
229971-86-2 229971-87-3 263917-87-9
263917-88-0 263917-89-1 263917-90-4
263917-91-5 263917-92-6 263917-93-7
381224-65-3 381224-66-4 381224-67-5
381224-69-7 381224-80-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulating agent; compds. and methods for modulating cadherin-mediated cell adhesion using **cyclic** peptides containing HAV sequence and antibodies to this sequence and uses thereof)

IT **382656-71-5**
RL: PRP (Properties)
(unclaimed sequence; compds. and methods for modulating cell adhesion)

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:934014 HCAPLUS
DOCUMENT NUMBER: 136:48463
TITLE: **Cyclic** peptide compounds and method for modulating neurite outgrowth
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 115,395.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6333307	B1	20011225	US 1999-250059		19990212
US 6031072	A	20000229	US 1997-893534		19970711
US 6169071	B1	20010102	US 1997-996679		19971223
US 6207639	B1	20010327	US 1998-115395		19980714
PRIORITY APPLN. INFO.:			US 1996-21612P	P	19960712
			US 1997-893534	A2	19970711
			US 1997-996679	A2	19971223
			US 1998-115395	A2	19980714

OTHER SOURCE(S): MARPAT 136:48463
AB Modulating agents comprising **cyclic** peptides, and compns. comprising such modulating agents, are provided. The **cyclic** peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for modulating and/or directing neurite outgrowth in a variety of contexts are also provided.

IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
250271-33-1 250271-34-2 250271-35-3
250271-36-4 250271-37-5 250271-39-7
250271-41-1 351974-94-2 351974-95-3
351974-97-5 382656-70-4
RL: PRP (Properties)
(Unclaimed; **cyclic** peptide compds. and method for modulating neurite outgrowth)

IT **229971-59-9P 229971-81-7P 229971-83-9P**
229971-84-0P 229971-85-1P 229971-86-2P
229971-87-3P 229971-89-5P 229971-90-8P
263917-87-9P 263917-88-0P 263917-89-1P
263917-90-4P 263917-91-5P 263917-92-6P
263917-93-7P 331229-54-0P 381224-69-7P
381224-80-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(**cyclic** peptide compds. and method for modulating neurite outgrowth)

IT **214684-49-8 214684-49-8D**, derivs. **229971-60-2 229971-60-2D**, derivs. **229971-61-3 229971-61-3D**, derivs. **229971-62-4 229971-62-4D**, derivs. **229971-63-5 229971-63-5D**, derivs. **229971-64-6 229971-64-6D**, derivs. **229971-67-9 229971-67-9D**, derivs. **381224-65-3 381224-65-3D**, derivs. **381224-66-4 381224-66-4D**, derivs. **381224-67-5 381224-67-5D**, derivs.
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**cyclic** peptide compds. and method for modulating neurite outgrowth)

IT **382656-71-5**
RL: PRP (Properties)
(unclaimed protein sequence; **cyclic** peptide compds. and method for modulating neurite outgrowth)

IT **202528-19-6 202528-20-9 382656-75-9 382656-76-0**
RL: PRP (Properties)
(unclaimed sequence; **cyclic** peptide compds. and method for modulating neurite outgrowth)

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:763034 HCAPLUS
DOCUMENT NUMBER: 135:298822
TITLE: Cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.; Farookhi, Riaz; Ali, Anmar**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077146	A2	20011018	WO 2001-US11669	20010409
WO 2001077146	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6610821	B1	20030826	US 2000-544782	20000407
CA 2405476	AA	20011018	CA 2001-2405476	20010409
EP 1311545	A2	20030521	EP 2001-926823	20010409

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003531120	T2	20031021	JP 2001-575616		20010409
PRIORITY APPLN. INFO.:			US 2000-544782	A	20000407
			US 1996-21612P	P	19960712
			US 1997-893534	A2	19970711
			US 1997-996679	A2	19971223
			US 1999-248074	A2	19990210
			US 1999-357717	A2	19990720
			US 1999-458870	A2	19991210
			WO 2001-US11669	W	20010409

OTHER SOURCE(S): MARPAT 135:298822

AB **Cyclic** peptides comprising a cadherin cell adhesion recognition sequence HAV, and compns. comprising such **cyclic** peptides, are provided. Methods for using such peptides for modulating cadherin-mediated endothelial cell adhesion in a variety of contexts are also provided.

IT **229971-84-0P 229971-86-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion)

IT **214684-49-8P 229971-59-9P 229971-61-3P**
229971-62-4P 229971-63-5P 229971-67-9P
229971-89-5P 229971-90-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion)

IT **229971-60-2 229971-64-6 229971-65-7**
229971-81-7 229971-83-9 229971-85-1
263917-87-9 263917-88-0 263917-89-1
263917-90-4 331229-54-0 365544-42-9
365544-43-0 365544-44-1 365544-45-2
365544-46-3 365544-47-4 365544-48-5
365544-49-6 365544-51-0 365544-52-1
365544-53-2 365544-54-3 365544-55-4
365544-56-5 365544-57-6 365544-58-7
365544-59-8 365544-60-1 365544-61-2
365544-62-3 365544-63-4 365544-64-5
365544-65-6 365544-66-7 365544-72-5
365544-73-6 365544-74-7 365544-75-8
365544-76-9 365544-77-0 365544-78-1
365544-79-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides and methods for modulating endothelial cell adhesion)

L19 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:545724 HCAPLUS
DOCUMENT NUMBER: 135:147398
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): **Gour, Barbara J.; Blaschuk, Orest W.** ; **Ali, Anmar**; Ni, Feng; Chen, Zhigang;

Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
WO 2001053331	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-491078 A 20000124
OTHER SOURCE(S): MARPAT 135:147398

AB Peptidomimetics of **cyclic** peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a **cyclic** peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **229971-59-9 229971-81-7 229971-83-9**
229971-84-0 229971-85-1 229971-86-2
229971-87-3 229971-89-5 229971-90-8
263917-87-9 263917-88-0 263917-89-1
263917-90-4 263917-92-6 263917-93-7
331229-54-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
250271-33-1 250271-34-2 250271-35-3
250271-36-4 250271-37-5 250271-39-7
250271-41-1 351974-94-2 351974-95-3
351974-97-5 351974-98-6 351974-99-7
351975-00-3 351975-01-4 351975-02-5
351975-03-6 351975-04-7 351975-05-8
352000-59-0 352000-60-3 352335-43-4
352335-47-8
RL: PRP (Properties)
(unclaimed sequence; peptidomimetic modulators of cell adhesion)

L19 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:222003 HCAPLUS

DOCUMENT NUMBER: 134:261263
TITLE: **Cyclic** peptides and methods for modulating neurite outgrowth
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): Mcgill University, Can.
SOURCE: U.S., 49 pp., Cont.-in-part of U.S. 6,031,072.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6207639	B1	20010327	US 1998-115395	19980714
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6333307	B1	20011225	US 1999-250059	19990212
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A2 19970711
			US 1997-996679	A2 19971223
			US 1998-115395	A2 19980714

OTHER SOURCE(S): MARPAT 134:261263

AB Modulating agents comprising **cyclic** peptides, and compns. comprising such modulating agents are provided. The **cyclic** peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for modulating and/or directing neurite outgrowth in a variety of contexts are also provided.

IT **331474-58-9 331474-59-0 331474-60-3**
331474-61-4 331474-62-5
RL: PRP (Properties)
(Unclaimed; **cyclic** peptides and methods for modulating neurite outgrowth)

IT **229971-81-7 229971-83-9 229971-84-0**
229971-85-1 229971-86-2 229971-87-3
263917-87-9 263917-88-0 263917-89-1
263917-90-4 263917-92-6 263917-93-7
331229-54-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**cyclic** peptides and methods for modulating neurite outgrowth)

IT **202527-94-4 202527-98-8 202528-00-5**
202528-03-8 202528-07-2 202528-10-7
250271-33-1 250271-34-2 250271-35-3
250271-36-4 250271-37-5 250271-39-7
250271-41-1
RL: PRP (Properties)
(unclaimed sequence; **cyclic** peptides and methods for modulating neurite outgrowth)

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:10082 HCAPLUS
DOCUMENT NUMBER: 134:80834
TITLE: **Cyclic** peptides and methods for modulating cell adhesion

INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 80 pp., Cont.-in-part of U.S. 6,031,072.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6169071	B1	20010102	US 1997-996679	19971223
US 6031072	A	20000229	US 1997-893534	19970711
US 6207639	B1	20010327	US 1998-115395	19980714
WO 9933875	A1	19990708	WO 1998-CA1207	19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9918664	A1	19990719	AU 1999-18664	19981223
US 6346512	B1	20020212	US 1999-248074	19990210
US 6562786	B1	20030513	US 1999-248015	19990210
US 6333307	B1	20011225	US 1999-250059	19990212
US 6417325	B1	20020709	US 1999-357717	19990720
US 6465427	B1	20021015	US 1999-458870	19991210
US 6610821	B1	20030826	US 2000-544782	20000407
US 2003087811	A1	20030508	US 2002-58821	20020129
US 6780845	B2	20040824		
US 2003065136	A1	20030403	US 2002-105008	20020322
US 2003224978	A1	20031204	US 2003-359546	20030204
US 2004106545	A1	20040603	US 2003-632678	20030801

PRIORITY APPLN. INFO.:

US 1996-21612P	P	19960712
US 1997-893534	A2	19970711
US 1997-996679	A2	19971223
US 1998-115395	A2	19980714
WO 1998-CA1207	W	19981223
US 1999-248015	A1	19990210
US 1999-248074	A2	19990210
US 1999-357717	A2	19990720
US 1999-458870	A2	19991210
US 2000-544782	A1	20000407
US 2003-359546	A2	20030204
US 2003-464071	A2	20030618

AB **Cyclic** peptides and compns. comprising them are provided. The **cyclic** peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using the peptides and compns. for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **229971-59-9P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(**cyclic** peptides and methods for modulating cell adhesion)

IT **229971-89-5P 229971-90-8P 315197-14-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(**cyclic** peptides and methods for modulating cell adhesion)

IT **229971-81-7P 229971-83-9P 229971-84-0P**
229971-85-1P 229971-86-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**cyclic** peptides and methods for modulating cell adhesion)

IT **202528-03-8 229971-60-2 229971-61-3**
229971-64-6 229971-65-7 229971-67-9
229971-68-0 229971-70-4 229971-72-6
317320-14-2 317320-15-3 317320-16-4
317320-17-5 317320-18-6
RL: PRP (Properties)
(unclaimed sequence; **cyclic** peptides and methods for modulating cell adhesion)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:646038 HCAPLUS
DOCUMENT NUMBER: 133:232873
TITLE: Compounds and methods for stimulating gene expression and cellular differentiation
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000053632	A1	20000914	WO 2000-CA222		20000307
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6683048	B1	20040127	US 1999-265107		19990309
PRIORITY APPLN. INFO.:			US 1999-265107	A	19990309
			US 1997-43361P	P	19970410
			US 1998-57363	A2	19980408

AB Modulating agents for inhibiting an interaction between α-catenin and β-catenin are provided. The modulating agents comprise one or more of (a) a β-catenin HAV motif; (b) a peptide analog or mimetic of a β-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a β-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **214684-19-2P 214684-20-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. and methods for stimulating gene expression and cellular differentiation)
IT **214684-19-2D**, internalization moiety-linked derivs.
214684-20-5D, internalization moiety-linked derivs.
214684-26-1 214684-26-1D, internalization moiety-linked derivs. **214684-27-2 214684-27-2D**, internalization moiety-linked derivs. **214684-29-4 214684-29-4D**, internalization moiety-linked derivs. **214684-37-4 214684-37-4D**, internalization moiety-linked derivs. **214684-38-5 214684-38-5D**, internalization moiety-linked derivs. **214684-40-9 214684-40-9D**, internalization moiety-linked derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for stimulating gene expression and cellular differentiation)
IT **202527-94-4 214684-28-3 214684-33-0 214684-35-2 214684-36-3 293304-94-6**
RL: PRP (Properties)
(unclaimed sequence; compds. and methods for stimulating gene expression and cellular differentiation)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:129326 HCAPLUS
DOCUMENT NUMBER: 132:275649
TITLE: A novel family of **cyclic** peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif
AUTHOR(S): Williams, Emma; Williams, Gareth; **Gour, Barbara J.**; **Blaschuk, Orest W.**; Doherty, Patrick
CORPORATE SOURCE: Molecular Neurobiology Group, Guy's King's and St. Thomas' School of Medicine, King's College London, London, SE1 9RT, UK
SOURCE: Journal of Biological Chemistry (2000), 275(6), 4007-4012
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The classical cadherins (e.g. N-, E-, and P- cadherin) are well established homophilic adhesion mols.; however, the mechanism that governs cadherin specificity remains contentious. The classical cadherins contain an evolutionarily conserved His-Ala-Val (HAV) sequence, and linear peptides harboring this motif are capable of inhibiting a variety of cadherin-dependent processes. We now demonstrate that short **cyclic** HAV peptides can inhibit N-cadherin function. Interestingly, the nature of the amino acids that flank the HAV motif determine both the activity and specificity of the peptides. For example, when the HAV motif is flanked by a single aspartic acid, which mimics the natural

HAVD sequence of N-cadherin, the peptide becomes a much more effective inhibitor of N-cadherin function. In contrast, when the HAV motif is flanked by a single serine, which mimics the natural HAVS sequence of E-cadherin, it loses its ability to inhibit the N-cadherin response. Our results demonstrate that subtle changes in the amino acids that flank the HAV motif can account for cadherin specificity and that small **cyclic** peptides can inhibit cadherin function. An emerging role for cadherins in a number of pathol. processes suggests that the **cyclic** peptides reported in this study might be developed as therapeutic agents.

IT **229971-81-7 229971-83-9 229971-84-0**
229971-85-1 229971-86-2 229971-87-3
229971-90-8 263917-87-9 263917-88-0
263917-89-1 263917-90-4 263917-91-5
263917-92-6 263917-93-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(novel family of **cyclic** peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:468472 HCAPLUS
DOCUMENT NUMBER: 131:82993
TITLE: Cadherin cell adhesion recognition sequence-containing **cyclic** peptides for modulating synaptic stability and cell adhesion
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9933875	A1	19990708	WO 1998-CA1207		19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6169071	B1	20010102	US 1997-996679		19971223
AU 9918664	A1	19990719	AU 1999-18664		19981223
PRIORITY APPLN. INFO.:			US 1997-996679	A	19971223
			US 1996-21612P	P	19960712
			US 1997-893534	A2	19970711
			WO 1998-CA1207	W	19981223

AB **Cyclic** peptides and compns. comprising such **cyclic** peptides are provided. The **cyclic** peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for modulating synaptic stability are also provided.

IT **214684-49-8 229971-58-8 229971-59-9**
229971-60-2 229971-60-2D, derivs. **229971-61-3**
229971-61-3D, derivs. **229971-62-4 229971-62-4D**
, derivs. **229971-63-5 229971-63-5D**, derivs.
229971-64-6 229971-64-6D, derivs. **229971-65-7**
229971-65-7D, derivs. **229971-67-9 229971-67-9D**
, derivs. **229971-68-0 229971-68-0D**, derivs.
229971-69-1 229971-69-1D, derivs. **229971-70-4**
229971-70-4D, derivs. **229971-71-5 229971-71-5D**
, derivs. **229971-72-6 229971-72-6D**, derivs.
229971-81-7 229971-83-9 229971-84-0
229971-85-1 229971-86-2 229971-87-3
229971-89-5 229971-90-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin cell adhesion recognition sequence-containing **cyclic** peptides for modulating synaptic stability and cell adhesion)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:682414 HCAPLUS
DOCUMENT NUMBER: 129:314961
TITLE: Cell adhesion-modulating agent comprising antibody or antigen-binding fragment and peptide inhibiting interaction between α-catenin and β-catenin
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara J.**
PATENT ASSIGNEE(S): Mcgill University, Can.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9845319	A2	19981015	WO 1998-CA322		19980414
WO 9845319	A3	19981217			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2286291	AA	19981015	CA 1998-2286291		19980414
AU 9869147	A1	19981030	AU 1998-69147		19980414
EP 975660	A2	20000202	EP 1998-914747		19980414
EP 975660	B1	20041110			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
AT 282045	E	20041115	AT 1998-914747		19980414
PRIORITY APPLN. INFO.:			US 1997-43361P	P	19970410
			WO 1998-CA322	W	19980414

AB Modulating agents for inhibiting an interaction between α-catenin and β-catenin are provided. The modulating agents comprise one or

more of: (a) a β-catenin HAV motif; (b) a peptide analog or mimetic of a β-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a β-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided. The modulating agents are useful for inhibiting cell adhesion between epithelial cells, endothelial cells, neural cells, tumor cells and lymphocytes, and for treating multiple sclerosis, bladder tumor, ovarian tumor, melanomas, carcinomas, leukemia, and demyelinating neurol. diseases.

IT **202527-94-4 214684-19-2 214684-20-5**
214684-26-1 214684-27-2 214684-28-3
214684-29-4 214684-33-0 214684-35-2
214684-36-3 214684-37-4 214684-38-5
214684-40-9 214684-45-4 214684-46-5
214684-47-6 214684-48-7 214684-49-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell adhesion-modulating agent comprising antibody or antigen-binding fragment and linear or **cyclic** peptides inhibiting interaction between α-catenin and β-catenin)

L19 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:71150 HCAPLUS
DOCUMENT NUMBER: 128:149597
TITLE: **Cyclic** peptides for modulating cell adhesion
INVENTOR(S): **Blaschuk, Orest W.; Gour, Barbara Joan**
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9802452	A2	19980122	WO 1997-CA489		19970711
WO 9802452	A3	19980305			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2259966	AA	19980122	CA 1997-2259966		19970711
AU 9733322	A1	19980209	AU 1997-33322		19970711
AU 722985	B2	20000817			
EP 937103	A2	19990825	EP 1997-929070		19970711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2001500475	T2	20010116	JP 1998-505472		19970711
PRIORITY APPLN. INFO.:			US 1996-21612P	P	19960712
			WO 1997-CA489	W	19970711

OTHER SOURCE(S): MARPAT 128:149597
AB **Cyclic** peptides and compns. comprising such **cyclic** peptides are provided. The **cyclic** peptides comprise a cadherin

cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided. **Cyclic** peptide N-Ac-CHAVC-NH2 was prepared This peptide was shown to inhibit neurite extension of mouse cerebellar neurons and to disrupt bovine endothelial cell adhesion, human ovarian cancer cell adhesion, and angiogenesis.

IT **202527-94-4P 202527-98-8P 202528-00-5P**
202528-03-8P 202528-07-2P 202528-10-7P
202528-18-5P 202528-19-6P 202528-20-9P
202528-21-0P 202528-22-1P 202528-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**cyclic** peptides for modulating cell adhesion)

L19 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:674297 HCAPLUS
DOCUMENT NUMBER: 115:274297
TITLE: Three amino acid substitutions in domain I of calmodulin prevent the activation of chicken smooth muscle myosin light chain kinase
AUTHOR(S): VanBerkum, Mark F. A.; Means, Anthony R.
CORPORATE SOURCE: Dep. Cell Biol., Baylor Coll. Med., Houston, TX, 77030, USA
SOURCE: Journal of Biological Chemistry (1991), 266(32), 21488-95
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB TaM-BMI is a genetically engineered chimeric protein consisting of the first 55 amino acids of cardiac troponin C (but with the normally inactive first Ca2+-binding domain reactivated by site-directed mutagenesis) ligated to the last three domains of chicken calmodulin. This protein binds chicken smooth muscle myosin light chain kinase (smMLCK) but fails to activate the enzyme, thus functioning as a potent competitive inhibitor (Ki = 66 nM). Twenty-nine mutants of calmodulin were produced, designed to identify the minimal number of alterations which must be introduced in the first domain to convert the protein to a competitive inhibitor of smMLCK. Alterations of three amino acids predicted to lie on the external surface of calmodulin (E14A,T34K,S38M) recapitulated the phenotype of TaM-BMI and exhibited a Ki of 38 nM. Both the triple mutant and TaM-BMI activated phosphodiesterase and bound a synthetic peptide analog of the calmodulin-binding region of smMLCK with an affinity similar to that of native calmodulin (Kact and Kd values of approx. 2 and 3 nM resp.). When a synthetic peptide analog of the myosin light chain phosphorylation site was used as substrate rather than the 20-kDa light chains, TaM-BMI and the triple mutant were partial agonists: the Km for the peptide substrate was increased 100- and 60-fold, and catalytic activity was 45 and 60%, resp., relative to calmodulin. These data suggest TaM-BMI and E14A/T34K/S38M may interact with the calmodulin-binding domain of smMLCK in a manner similar to calmodulin. However, alterations in electrostatic and hydrophobic interactions created by the three amino acid substitutions prevent the conformational change in the enzyme usually produced by calmodulin binding. Lack of such changes results in loss of catalytic activity and light chain binding. Addnl., the results show that altering only 3 amino acids residues converts calmodulin to an enzyme-selective antagonist, thus demonstrating the ability to sep. calmodulin binding to smMLCK from calmodulin-induced activation of the enzyme.

IT **137506-00-4**

RL: BIOL (Biological study)
(**cyclic** nucleotide phosphodiesterase activation by calmodulin and mutant forms response to, myosin light chain kinase calmodulin-binding domain of smooth muscle in relation to)